--(BUSINESS WIRE)--Corcept Therapeutics Incorporated ... will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian ...

Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in ...

He spoke to EW and shared, I would hope that Season 3 comes sooner. Certainly, a big part of it [delayed season 2] was the fact that we had the strike, which shut us down for five or six months of ...